• Pawelec G, Wagner W. Is HLA-DR4 or the HLA-DRB1*0402 allele associated with decreased risk for CML? Leukemia 15:192, 2001
  • Pawelec G, Effros RB, Globerson A: A multidisciplinary approach to immunity and ageing: ImAginEering. Mech Ageing Dev 121:1, 2000
  • Pawelec G, Ferguson FG, Wikby A: The SENIEUR protocol after 16 years. Mech Ageing Dev. 122:132, 2001
  • Pawelec G, Müller L, Wagner W: CD4+ T cells and MHC class II-restricted tumour antigens have a role in haematological malignancies as well as solid tumours. Trends Immunol 22:422, 2001
  • Pawelec G, Solana R: Immunoageing: the cause or effect of morbidity? Trends Immunol 22:348, 2001
  • Pawelec G: Meeting report: Progress in vaccination against cancer, PIVAC 2001, July 2001, Cambridge, UK. Trends Mol Med 7:486, 2001
  • De Grey ADNJ, Baynes JW, Berd D, Heward CB, Pawelec G, Stock G: Is human aging still mysterious enough to be left only to scientists? Bioessays 24:1, 2002
  • Pawelec G, Ouyang Q, Colonna-Roman G, Candore G, Lio D, Caruso C: Is human immunosenescence clinically relevant? Looking for "immunological risk phenotypes". Trends Immunol 23:330, 2002
  • Rees RC, Pawelec G, Müller L, Robins A: Progress in vaccination against cancer (PIVAC) 2001, Robinson College, University of Cambridge, UK. Cancer Immunol Immunother 51:58-61, 2002
  • Pawelec G: Senescence: the cost of being young and healthy? Eur Cytokine Netw. 13:387, 2002
  • Pawelec G, Rees RC: Cancer vaccination progress. Trends Mol Med. 8:545-6, 2002
  • Pawelec G: Immunosenescence and human longevity. Biogerontology 4: 167-179, 2003
  • Hasenmaile S, Pawelec G, Wagner W. A lack of telomeric non-reciprocal recombination (TENOR) may account for the premature proliferation blockade of Werner's syndrome fibroblasts. Biogerontology 4:253-273, 2003
  • Pawelec G, Ouyang Q: Immunosenescence in Montecatini. Biogerontology 4: 121-123, 2003
  • Pawelec G, Caruso C: Immunology and ageing in Europe: ImAginE-ation in the EU. Mech Ageing Dev 124: 357-360, 2003
  • Rees RC, Robbins RA, Pawelec G, Müller L, Li G, Spendlove I. International conference: Progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK. Cancer Immunol Immunother 52:403-407, 2003
  • Pawelec G: Extrathymic T cell differentiation in vitro. Nature Reviews Immunology. Published online: 2004 doi:10.1038/nri1257-c1
  • Wagner WM, Ouyang Q, Sekeri-Pataryas K, Sourlingas TG, Pawelec G: Basic biology and clinical impact of immunosenescence. Biogerontology 5:63-66, 2004
  • Pawelec G, Gouttefangeas C: Strategies for immune therapy: Wurzburg, Germany, 29 February-3 March 2004. Cancer Immunol Immunother 53:755-758, 2004
  • Ouyang Q, Wagner WM, Pawelec G: Reply to Almanzar's et al. letter to the editor: IFN-gamma production by CMV-specific CD8(+) T cells is high in elderly donors. Exp Gerontol. 39:867-868, 2004
  • Pawelec G: Meeting Report: British Society for Immunology Annual Congress, Harrogate, UK, 2–5 December 2003. Cancer Immunol Immunother 53:471-472, 2004
  • Pawelec G, Forsey R. Immunosenescence: what is it and what can be done about it? Session 20 of the BSI Annual Congress, Harrogate, December, 2003. Rejuvenation Res 7:61-4, 2004
  • Pawelec G, Mariani E, McLeod J, Ben-Yehuda A, Fulop T, Aringer M, Barnett Y. Engineering anticancer T cells for extended functional longevity. Ann N Y Acad Sci 1019:178-85, 2004
  • Pawelec G, Akbar A, Caruso C, Effros R, Grubeck-Loebenstein B, Wikby A: Is immunosenescence infectious? Trends Immunol. 25:406-10, 2004 40)
  • Britten CM, Mueller L, Knights A, Pawelec G: Cancer Immunotherapy 2004: Mainz, Germany, 6-7 May 2004. Cancer Immunol Immunother. 53:1153-1158, 2004
  • Mocchegiani E, Marcellini F, Pawelec G: Nutritional zinc, oxidative stress and immunosenescence: biochemical, genetic, and lifestyle implications for healthy ageing. Biogerontology 5:271-3, 2004